

Supplementary Table 1. Baseline characteristics between final population and population without HbA1c or ABG data

Variables	Final population (n=5562)	Population without HbA1c or ABG data (n=488)	P value
Age, years	58.01 ± 10.10	57.77 ± 9.53	0.596
Male, n (%)	4265 (76.7%)	371 (76.0%)	0.742
BMI, kg/m ²	25.91 ± 3.23	25.67 ± 3.35	0.117
Diagnosis on admission			
UA, n (%)	3873 (69.6%)	396 (81.1%)	
NSTEMI, n (%)	1279 (23.0%)	79 (16.2%)	<.001
STEMI, n (%)	410 (7.4%)	13 (2.7%)	
Family history, n (%)	1327 (23.9%)	100 (20.5%)	0.093
Previous MI, n (%)	702 (12.6%)	67 (13.7%)	0.481
Previous PCI, n (%)	1271 (22.9%)	92 (18.9%)	0.043
Previous CABG, n (%)	215 (3.9%)	17 (3.5%)	0.674
Hypertension, n (%)	3585 (64.5%)	298 (61.1%)	0.134
Hyperlipemia, n (%)	3706 (66.6%)	335 (68.6%)	0.364
DM, n (%)	2184 (39.3%)	135 (27.7%)	<.001
Previous stroke, n (%)	598 (10.8%)	47 (9.6%)	0.442
Current smoker, n (%)	3301 (59.3%)	268 (54.9%)	0.056
LM disease, n (%)	326 (5.9%)	25 (5.1%)	0.504
3-vessel disease, n (%)	2275 (40.9%)	176 (36.1%)	0.037
CTO disease, n (%)	294 (5.3%)	28 (5.7%)	0.67
ISR disease, n (%)	198 (3.6%)	13 (2.9%)	0.301
SYNTAX score	10 (6, 16) *	8 (5, 16) *	0.002
Type of stents			
First generation DES	487 (8.8%)	46 (9.4%)	
Second generation DES	4905 (88.2%)	426 (87.3%)	0.843
Hybrid DES	170 (3.1%)	16 (3.3%)	
Number of stents	2 (1, 2) *	2 (1, 2) *	0.625
Diameter of stents, mm	3.03 ± 0.52	3.06 ± 0.49	0.198
Length of stents, mm	28 (18, 40)	28 (18, 38)	0.224
IABP, n (%)	71 (1.3%)	4 (0.8%)	0.382
IVUS, n (%)	219 (3.9%)	24 (4.9%)	0.290
SBP, mmHg	126.82 ± 16.83	125.34 ± 16.99	0.063
DBP, mmHg	77.60 ± 10.87	77.35 ± 11.26	0.627
LVEF, %	62.63 ± 7.33	63.52 ± 6.65	0.005
Low T3 syndrome	159 (2.9%)	10 (2.0%)	0.298
EGFR, ml/min/1.73m ²	95.92 ± 19.92	96.70 ± 19.62	0.407
TG, mmol/L	1.56 (1.16, 2.13) *	1.57 (1.08, 2.19) *	0.263
TC, mmol/L	4.25 ± 1.06	4.18 ± 1.03	0.161
HDL-C, mmol/L	1.03 ± 0.28	1.05 ± 0.24	0.082
LDL-C, mmol/L	2.54 ± 0.91	2.49 ± 0.91	0.244

Uric acid, umol/L	339.98 ± 84.66	317.26 ± 75.97	<0.001
Hs-CRP, mg/L	1.83 (0.88, 4.42) *	1.77 (0.85, 4.39) *	0.356
Hb, g/L	136.79 ± 14.93	137.62 ± 15.42	0.240
DAPT, n (%)	5522 (99.3%)	484 (99.2%)	0.802
Statin, n (%)	5374 (96.6%)	468 (95.9%)	0.404
β - blocker, n (%)	4837 (87.0%)	412 (84.4%)	0.065
ACEI/ARB, n (%)	3325 (59.8%)	285 (58.4%)	0.552
CCB, n (%)	3021 (54.3%)	248 (50.8%)	0.137
Glucose-lowering therapy			
Insulin	575 (26.3%)	35 (25.9%)	
Oral hypoglycemic drugs	1003 (45.9%)	53 (39.3%)	0.173
Diet control	606 (27.7%)	47 (34.8%)	

Data are expressed as mean ± SD, medians with interquartile ranges * or n (%)

Abbreviations: SHR, stress hyperglycemia ratio; BMI, body mass index; UA, unstable angina; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; IDDM, insulin dependent diabetes mellitus; LM, left main; CTO, chronic total occlusion; ISR, in-stent restenosis; SYNTAX, Synergy between PCI with TAXUS™ and Cardiac Surgery; IABP, intra-aortic balloon pump; IVUS, intravascular ultrasound; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVEF, left ventricle ejection fraction; EGFR, estimated glomerular filtration rate; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ABG, Hs-CRP, high sensitivity C-reactive protein. Hb, hemoglobin; DAPT, dual antiplatelet therapy; ACEI, Angiotensin-Converting Enzyme Inhibitors; ARB, Angiotensin Receptor Blockers; CCB, Calcium Channel Blockers.

Supplementary Table 2. The adverse cardiovascular and cerebrovascular events among the five groups

Endpoints	Q1 (n=1113)	Q2 (n=1112)	Q3 (n=1113)	Q4 (n=1112)	Q5 (n=1112)	P value
MACCEs at two-year follow-up	136 (12.3%)	107 (9.6%)	98 (8.9%)	127 (11.4%)	175 (15.7%)	<.001
MACEs at two-year follow-up	108 (9.7%)	84 (7.6%)	76 (6.8%)	104 (9.4%)	129 (11.6%)	<.001
Cardiac death and nonfatal MI at two-year follow-up	57 (5.1%)	41 (3.7%)	39 (3.5%)	57 (5.1%)	88 (7.9%)	<.001
In-hospital cardiac death and nonfatal MI	45 (4.0%)	31 (2.8%)	27 (2.4%)	47 (4.2%)	68 (6.1%)	<.001

Abbreviations: MACCE, major adverse cardiovascular and cerebrovascular events; MACE, major adverse cardiovascular events; MI, myocardial infarction

Supplementary Table 3. Multivariable Cox regression and logistic regression analyses for different endpoints adjusted variables from the lasso model

SHR group	MACCEs at two-tear follow-up		MACEs at two-year follow-up		Cardiac death and nonfatal MI at two-year follow-up		In-hospital cardiac death and nonfatal MI	
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	OR (95% CI)	P
	1st quintile	1.39 (1.07-1.80)	0.015	1.42 (1.06-1.91)	0.020	1.45 (0.96-2.18)	0.075	1.46 (0.98-2.82)
2nd quintile	1.11 (0.84-1.46)	0.461	1.12 (0.82-1.53)	0.470	1.05 (0.68-1.63)	0.815	1.17 (0.70-1.96)	0.549
3rd quintile	Reference		Reference		Reference		Reference	
4th quintile	1.33 (1.02-1.73)	0.035	1.39 (1.04-1.88)	0.029	1.45 (0.96-2.18)	0.075	1.65 (1.02-2.67)	0.040
5th quintile	1.54 (1.19-1.99)	0.001	1.49 (1.11-1.99)	0.008	1.39 (1.16-2.53)	0.007	1.91 (1.19-3.05)	0.007
P value for trend	0.201		0.396		0.134		0.082	

Abbreviations: SHR, stress hyperglycemic ratio; MACCEs, major adverse cardiovascular and cerebrovascular events; MACEs, major adverse cardiovascular events; MI, myocardial infarction; HR, hazard ratio; CI, confidence interval.